HAOHAI BIOTEC (06826) announced that on September 10, 2026, it utilized approximately HK$795,700 to repurchase 48,000 shares of the company.
The buyback transaction reflects the company's ongoing capital management strategy, aimed at enhancing shareholder value by reducing the number of shares outstanding in the market.
This move is part of a series of repurchase activities that the company has undertaken, demonstrating its confidence in its financial position and future prospects.